Analysts forecast that TherapeuticsMD Inc (NASDAQ:TXMD) will announce $4.59 million in sales for the current quarter, according to Zacks. Four analysts have provided estimates for TherapeuticsMD’s earnings, with the lowest sales estimate coming in at $4.22 million and the highest estimate coming in at $5.09 million. TherapeuticsMD reported sales of $4.42 million during the same quarter last year, which indicates a positive year over year growth rate of 3.8%. The firm is expected to report its next earnings results on Monday, November 5th.

On average, analysts expect that TherapeuticsMD will report full-year sales of $19.06 million for the current financial year, with estimates ranging from $17.47 million to $20.70 million. For the next financial year, analysts forecast that the business will report sales of $128.64 million, with estimates ranging from $74.00 million to $180.20 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover TherapeuticsMD.

TherapeuticsMD (NASDAQ:TXMD) last issued its quarterly earnings results on Monday, July 30th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). TherapeuticsMD had a negative return on equity of 80.75% and a negative net margin of 582.86%. The business had revenue of $3.80 million for the quarter, compared to analyst estimates of $4.23 million. During the same period in the previous year, the company posted ($0.10) earnings per share. The business’s revenue for the quarter was down 11.6% on a year-over-year basis.

Several equities analysts recently issued reports on TXMD shares. BidaskClub downgraded TherapeuticsMD from a “hold” rating to a “sell” rating in a research report on Friday, June 15th. JPMorgan Chase & Co. started coverage on TherapeuticsMD in a research report on Friday, June 15th. They issued an “overweight” rating and a $11.00 target price on the stock. ValuEngine downgraded TherapeuticsMD from a “buy” rating to a “hold” rating in a research report on Saturday, July 28th. Cantor Fitzgerald set a $26.00 target price on TherapeuticsMD and gave the company a “buy” rating in a research report on Monday, July 30th. Finally, Oppenheimer set a $12.00 target price on TherapeuticsMD and gave the company a “buy” rating in a research report on Monday, July 30th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. TherapeuticsMD presently has a consensus rating of “Buy” and an average price target of $15.40.

In other TherapeuticsMD news, CEO Robert G. Finizio sold 184,000 shares of the company’s stock in a transaction on Friday, September 7th. The shares were sold at an average price of $6.24, for a total value of $1,148,160.00. Following the sale, the chief executive officer now directly owns 18,485,559 shares of the company’s stock, valued at $115,349,888.16. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider John C.K. Iv Milligan sold 250,000 shares of the company’s stock in a transaction on Wednesday, October 10th. The shares were sold at an average price of $5.85, for a total transaction of $1,462,500.00. Following the completion of the sale, the insider now directly owns 1,597,419 shares in the company, valued at $9,344,901.15. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,450,000 shares of company stock worth $9,101,374. 22.85% of the stock is owned by corporate insiders.

A number of large investors have recently bought and sold shares of the business. BlackRock Inc. boosted its holdings in TherapeuticsMD by 4.4% in the second quarter. BlackRock Inc. now owns 14,533,524 shares of the company’s stock valued at $90,690,000 after purchasing an additional 608,470 shares during the last quarter. Voya Investment Management LLC boosted its holdings in TherapeuticsMD by 7.7% in the second quarter. Voya Investment Management LLC now owns 3,419,174 shares of the company’s stock valued at $21,336,000 after purchasing an additional 242,995 shares during the last quarter. Northern Trust Corp boosted its holdings in TherapeuticsMD by 4.0% in the second quarter. Northern Trust Corp now owns 2,086,552 shares of the company’s stock valued at $13,021,000 after purchasing an additional 81,062 shares during the last quarter. OppenheimerFunds Inc. boosted its holdings in TherapeuticsMD by 17.4% in the second quarter. OppenheimerFunds Inc. now owns 1,932,439 shares of the company’s stock valued at $12,058,000 after purchasing an additional 286,123 shares during the last quarter. Finally, Stifel Financial Corp boosted its holdings in TherapeuticsMD by 1.3% in the first quarter. Stifel Financial Corp now owns 1,862,644 shares of the company’s stock valued at $9,067,000 after purchasing an additional 23,141 shares during the last quarter. 66.14% of the stock is currently owned by institutional investors.

Shares of NASDAQ TXMD traded down $0.17 during mid-day trading on Friday, hitting $5.42. The stock had a trading volume of 3,180,026 shares, compared to its average volume of 2,525,105. The company has a debt-to-equity ratio of 0.94, a current ratio of 7.88 and a quick ratio of 7.79. TherapeuticsMD has a twelve month low of $4.34 and a twelve month high of $7.66. The company has a market cap of $1.52 billion, a price-to-earnings ratio of -14.65 and a beta of 1.40.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.

See Also: Outstanding Shares

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.